A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short‐term study

IR has served on the advisory board for Sanofi Aventis, Abbott, Menarini, and has spoken for Eli Lilly, NovoNordisk, Sanofi Aventis. GBB has received honoraria for scientific lectures from Sanofi Aventis and Menarini. RB has served on the advisory board for NovoNordisk, Eli Lilly, Sanofi Aventis, Abbott, Medtronic, Movi, Roche and Ypsomed and has spoken for Eli Lilly, Abbott and Sanofi Aventis. The other authors declare that they have no competing interests. The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14839. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.